Pasireotide: A review of its use in Cushing's disease

Drugs

Volumn 73, Issue 6, 2013, Pages 563-574

  McKeage, Kate ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; D DIMER; DEXAMETHASONE; HYDROCORTISONE; OCTREOTIDE; PASIREOTIDE; PLACEBO; PROTEIN C; PROTEIN S; SOMATOSTATIN RECEPTOR 5;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BINDING AFFINITY; BODY WEIGHT; CELL PROLIFERATION; CHOLELITHIASIS; CORTICOTROPIN RELEASE; CUSHING DISEASE; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; HYPERGLYCEMIA; IC 50; INCIDENCE; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; HUMANS; PITUITARY ACTH HYPERSECRETION; PITUITARY GLAND, ANTERIOR; SOMATOSTATIN;

EID: 84878281667     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0052-0     Document Type: Review

References (34)

1. BM Biller AB Grossman PM Stewart, et al. 2008 Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement J Clin Endocrinol Metab 93 7 2454 2462 18413427 10.1210/jc.2007-2734 1:CAS:528:DC%2BD1cXoslyktLo%3D
2. RA Feelders SJ Pulgar A Kempel, et al. 2012 The burden of Cushing's disease: clinical and health-related quality of life aspects Eur J Endocrinol 167 3 311 326 22728347 10.1530/EJE-11-1095 1:CAS:528:DC%2BC38XhsVWltLnK
3. J Lindholm S Juul JO Jorgensen, et al. 2001 Incidence and late prognosis of Cushing's syndrome: a population-based study J Clin Endocrinol Metab 86 1 117 123 11231987 10.1210/jc.86.1.117 1:CAS:528:DC%2BD3MXhtVGnsrs%3D
4. Y Reznik J Bertherat F Borson-Chazot, et al. 2013 Management of hyperglycaemia in Cushing's disease: expert's proposals on the use of pasireotide Diabetes Metab 39 1 34 41 23228667 10.1016/j.diabet.2012.10.005 1:CAS:528:DC%2BC38XhvVWjtbvP
5. J Etxabe JA Vazquez 1994 Morbidity and mortality in Cushing's disease: an epidemiological approach Clin Endocrinol (Oxf) 40 4 479 484 10.1111/j.1365-2265.1994.tb02486.x 1:STN:280:DyaK2c3ksVSkuw%3D%3D
6. CG Patil DM Prevedello SP Lad, et al. 2008 Late recurrences of Cushing's disease after initial successful transsphenoidal surgery J Clin Endocrinol Metab 93 2 358 362 18056770 10.1210/jc.2007-2013 1:CAS:528:DC%2BD1cXit1Sntrk%3D
7. Arnaldi G, Boscaro M. New treatment guidelines on Cushing's disease. F1000 Med Rep. 2009. doi: 10.3410/M1-64.
8. LJ Hofland J van der Hoek R Feelders, et al. 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5 Eur J Endocrinol 152 4 645 654 15817922 10.1530/eje.1.01876 1:CAS:528:DC%2BD2MXjslansLg%3D
9. A Lacroix R Pivonello 2012 Medical treatment of Cushing's disease with pasireotide Eur Endocrinol 8 2 99 104
10. European Medicines Agency. Signifor solution for injection: summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/002052/WC500128056.pdf. Accessed 9 Jan 2013.
11. Novartis Pharmaceuticals Corporation. Signifor: full prescribing information. 2012. http://www.pharma.us.novartis.com/product/pi/pdf/signifor. pdf. Accessed 12 Jan 2013.
12. DL Batista X Zhang R Gejman, et al. 2006 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas J Clin Endocrinol Metab 91 11 4482 4488 16940446 10.1210/jc.2006-1245 1:CAS:528:DC%2BD28Xht1WhurvL
13. C Beglinger K Hu Y Wang, et al. 2012 Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, phase I study Endocrine 42 2 366 374 22527887 10.1007/s12020-012-9668-1 1:CAS:528: DC%2BC38XlvFais7s%3D
14. G Golor K Hu M Ruffin, et al. 2012 A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers Drug Des Devel Ther 6 71 79 22573933 10.2147/DDDT.S29125 1:CAS:528:DC%2BC38XmsF2qt7c%3D
15. Shenouda M, Maldonado M, Wang Y, et al. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels. Am J Ther. 2012. doi: 10.1097/MJT.0b013e31824c3eb4.
16. Henry RR, Mudaliar S, Wetli-Hermosillo K, et al. Mechanism and management of hyperglycaemia associated with pasireotide: results from studies in healthy volunteers [abstract no. P260]. European Congress of Endocrinology; 30 Apr 4-May 2011; Rotterdam.
17. RA Feelders C de Bruin AM Pereira, et al. 2010 Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease N Engl J Med 362 19 1846 1848 20463350 10.1056/NEJMc1000094 1:CAS:528:DC%2BC3cXmtVahu7c%3D
18. R van der Pas C de Bruin FWG Leebeek, et al. 2012 The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy J Clin Endocrinol Metab 97 4 1303 1310 22278425 10.1210/jc.2011-2753
19. Y Horsmans K Hu M Ruffin, et al. 2012 Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study J Clin Pharmacol 52 4 552 558 22282526 10.1177/0091270011400072 1:CAS:528:DC%2BC38XmsFersLY%3D
20. M Boscaro WH Ludlam B Atkinson, et al. 2009 Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial J Clin Endocrinol Metab 94 1 115 122 18957506 10.1210/jc.2008-1008 1:CAS:528: DC%2BD1MXptVKltQ%3D%3D
21. Boscaro M, Zhang Y, Sen K, et al. Long-term treatment of Cushing's disease with pasireotide (SOM230): results from a Phase II extension study [abstract no. P640]. European Congress of Endocrinology, Prague, 24-28 Apr 2010.
22. A Colao S Petersenn J Newell-Price, et al. 2012 A 12-month phase 3 study of pasireotide in Cushing's disease N Engl J Med 366 10 914 924 22397653 10.1056/NEJMoa1105743 1:CAS:528:DC%2BC38XktFOgur8%3D
23. Bertherat J, Schopohl J, Ludlam WH, et al. Long-term pasireotide use leads to significant and sustained improvements in the signs and symptoms of Cushing disease: 24-month results from a randomized phase III study [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23-26 Jun 2012.
24. Lacroix A, Ludlam W, Mantero F, et al. Initial response to pasireotide treatment is predictive of 12-month response: results of a large, randomized, double-blind, phase III study in patients with Cushing disease [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23-26 Jun 2012.
25. Schopohl J, Bertherat J, Ludlam W, et al. Long-term pasireotide use leads to improvements in the biochemical parameters of Cushing's disease: 24-month results from a randomized phase III study [abstract no. P1410]. In: 15th International Congress of Endocrinology and 14th European Congress of Endocrinology, Florence, 5-9 May 2012.
26. Pivonello R, Petersenn S, Newell-Price J, et al. Pasireotide treatment in Cushing disease is associated with significant improvements in hypertension: 12-month results from a large phase III study [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23-26 Jun 2012.
27. Gadelha M, Badia X, Zgliczynski W, et al. Pasireotide treatment is associated with clinically meaningful improvements in health-related quality of life in Cushing disease: results from a large, randomized, double-blind, phase III trial [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23-26 Jun 2012.
28. Bertherat J, Ludlam WH, Pivonello R, et al. Pasireotide as a long-term treatment for patients with Cushing disease: 24-month safety results from a randomized phase III study [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23-26 Jun 2012.
29. M Fleseriu S Petersenn 2012 Medical management of Cushing's disease: what is the future? Pituitary 15 3 330 341 22674211 10.1007/s11102-012-0397-5 1:CAS:528:DC%2BC38XhtlOlu77J
30. Trementino L, Cardinaletti M, Concettoni C, et al. Long-term efficacy of pasireotide in a patients with Cushing's disease and diabetes: results in the short term are not always predictive of long-term response [abstract no. P108]. J Clin Endokrinol Stoffw. 2012;5(Special Issue 3).
31. R Libe L Groussin J Bertherat 2012 Pasireotide in Cushing's disease [letter] N Engl J Med 366 22 2134 22646647 10.1056/NEJMc1204078 1:CAS:528:DC%2BC38Xos1eqtLo%3D
32. Ning G, Wang W, Maldonado M, et al. Long-term efficacy and safety of pasireotide in Cushing's disease: a 36-month case report [abstract no. P353]. In: 15th International Congress of Endocrinology and 14th European Congress of Endocrinology, Florence, 5-9 May 2012.
33. RA Feelders LJ Hofland 2013 Medical treatment of Cushing's disease J Clin Endocrinol Metab 98 2 425 438 23345100 10.1210/jc.2012-3126 1:CAS:528:DC%2BC3sXjtlOlurk%3D
34. Ligueros-Saylan M, Zhang Y, Newell-Price J, et al. Evaluation of the efficacy and safety of pasireotide LAR in patients with mild-to-moderate Cushing's disease: a randomized, double-blind, multicentre, phase III study design [abstract no. P1542.1]. In: 15th International Congress of Endocrinology and 14th European Congress of Endocrinology, Florence, 5-9 May 2012.